Biosimilars Market, will grow at 35.2% CAGR, to be valued at US$ 70 Billion by 2027: Impact of COVID – PharmiWeb.com

A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem Cell Foundation (NSCF), around 4% of the worlds population is affected by one of more than 80 different autoimmune diseases, the most common of which include multiple sclerosis, type 1 diabetes, scleroderma, Crohns disease, lupus, psoriasis and. rheumatoid arthritis.

Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/750

Autoimmune diseases are a family of more than 80 chronic, often debilitating and, in some cases, life-threatening illnesses. Moreover, growth of the biosimilars market is being driven by the increasing research and development and speedy approvals of biosimilars, especially in the North America. For instance, in 2019, the United States Food and Drug Administration (FDA) approved Amgens AVSOLA (infliximab-axxq), for all approved indications of the reference product, Remicade (infliximab), for the treatment of rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Crohns Disease, and chronic severe plaque psoriasis. However, stringent regulations and manufacturing complications are major factors expected to restrain the biosimilars market growth.

Furthermore, the biosimilar market, in Europe, is witnessing robust growth due to the growing adoption of biosimilars due low price and rapid entry of biosimilars in the region. For instance, in 2018, European Commission (EC) approved Sandozs Zessly, a biosimilar for use in Europe, confirming that Zessly matches safety, efficacy, and quality of reference medicine. Zessly is approved for the treatment of adult and pediatric Crohns disease, adult and pediatric ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. However, the adoption rate varies from country to country, always associated with regulatory and market access issues. This in turn is also expected to hamper the biosimilars market growth.

Growth of the biosimilars market can also be attributed to rich pipeline of biosimilar products and expiry/termination of existing drugs. As of June 2020, FDA has approved 27 biosimilars, plus four follow-on biologicals. The pipeline for biosimilars continues to grow, however, of the 27 approved biosimilars, only 17 have been launched so far. Biosimilars on average can cost 30% less than reference biologicals. Thus, pharmaceutical and biotechnology companies are focusing on developing safe and effective biosimilars, because a small variations in the manufacturing process can potentially alter the medicines safety and efficacy.

Major Key Players Include In Biosimilars Market: Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddys Laboratories, and Sanofi S.A.

Main points in Biosimilars Market Report Table of Content

Chapter 1 Industry Overview1.1 Definition1.2 Assumptions1.3 Research Scope1.4 Market Analysis by Regions1.5 Biosimilars Market Size Analysis from 2021 to 202711.6 COVID-19 Outbreak: Biosimilars Industry Impact

Chapter 2 Global Biosimilars Competition by Types, Applications, and Top Regions and Countries2.1 Global Biosimilars (Volume and Value) by Type2.3 Global Biosimilars (Volume and Value) by Regions

Chapter 3 Production Market Analysis3.1 Global Production Market Analysis3.2 Regional Production Market Analysis

Chapter 4 Global Biosimilars Sales, Consumption, Export, Import by Regions (2016-2021)Chapter 5 North America Biosimilars Market AnalysisChapter 6 East Asia Biosimilars Market AnalysisChapter 7 Europe Biosimilars Market AnalysisChapter 8 South Asia Biosimilars Market AnalysisChapter 9 Southeast Asia Biosimilars Market AnalysisChapter 10 Middle East Biosimilars Market AnalysisChapter 11 Africa Biosimilars Market AnalysisChapter 12 Oceania Biosimilars Market AnalysisChapter 13 South America Biosimilars Market AnalysisChapter 14 Company Profiles and Key Figures in Biosimilars BusinessChapter 15 Global Biosimilars Market Forecast (2021-2027)Chapter 16 ConclusionsResearch Methodology

Continued.

Buy instant copy of this research report with Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/750

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Link:
Biosimilars Market, will grow at 35.2% CAGR, to be valued at US$ 70 Billion by 2027: Impact of COVID - PharmiWeb.com